A detailed history of Mario Gabelli (Gamco Investors, Inc. Et Al) transactions in Dexcom Inc stock. As of the latest transaction made, Gamco Investors, Inc. Et Al holds 52,000 shares of DXCM stock, worth $3.59 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
52,000
Previous 52,000 -0.0%
Holding current value
$3.59 Million
Previous $7.21 Million 18.26%
% of portfolio
0.07%
Previous 0.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$67.99 - $132.89 $2.65 Million - $5.18 Million
39,000 Added 300.0%
52,000 $3.88 Million
Q4 2020

Feb 05, 2021

SELL
$78.0 - $104.5 $23,400 - $31,350
-300 Reduced 2.26%
13,000 $4.81 Million
Q3 2020

Nov 06, 2020

SELL
$95.51 - $112.95 $19,102 - $22,590
-200 Reduced 1.48%
13,300 $5.48 Million
Q2 2020

Aug 13, 2020

SELL
$62.68 - $105.34 $31,340 - $52,670
-500 Reduced 3.57%
13,500 $5.47 Million
Q4 2019

Feb 14, 2020

SELL
$36.62 - $57.29 $142,818 - $223,431
-3,900 Reduced 21.79%
14,000 $3.06 Million
Q3 2019

Nov 01, 2019

SELL
$35.53 - $43.8 $39,083 - $48,180
-1,100 Reduced 5.79%
17,900 $2.67 Million
Q2 2019

Aug 02, 2019

SELL
$27.84 - $38.92 $27,840 - $38,920
-1,000 Reduced 5.0%
19,000 $2.85 Million
Q1 2019

May 02, 2019

SELL
$28.07 - $38.18 $14,035 - $19,090
-500 Reduced 2.44%
20,000 $2.38 Million
Q4 2018

Jan 30, 2019

SELL
$26.99 - $37.37 $94,465 - $130,794
-3,500 Reduced 14.58%
20,500 $2.46 Million
Q3 2018

Nov 02, 2018

SELL
$23.35 - $36.72 $23,350 - $36,720
-1,000 Reduced 4.0%
24,000 $3.43 Million
Q2 2018

Aug 10, 2018

SELL
$17.54 - $25.22 $122,780 - $176,540
-7,000 Reduced 21.88%
25,000 $2.38 Million
Q3 2017

Nov 01, 2017

BUY
$11.36 - $18.98 $363,520 - $607,360
32,000
32,000 $1.57 Million

Others Institutions Holding DXCM

About DEXCOM INC


  • Ticker DXCM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 386,257,984
  • Market Cap $26.7B
  • Description
  • DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...
More about DXCM
Track Mario Gabelli's Portfolio

Track Mario Gabelli Portfolio

Follow Mario Gabelli (Gamco Investors, Inc. Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamco Investors, Inc. Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Gamco Investors, Inc. Et Al and Mario Gabelli with notifications on news.